Earnings summaries and quarterly performance for Monte Rosa Therapeutics.
Executive leadership at Monte Rosa Therapeutics.
Board of directors at Monte Rosa Therapeutics.
Research analysts covering Monte Rosa Therapeutics.
Recent press releases and 8-K filings for GLUE.
Monte Rosa Therapeutics Provides Clinical Program Updates and Financial Overview at TD Cowen Healthcare Conference
GLUE
New Projects/Investments
Revenue Acceleration/Inflection
- Monte Rosa Therapeutics, a molecular glue degrader company, has three programs currently in the clinic, all of which have produced positive clinical data.
- The company reported over $300 million in collaboration revenue over the last year, contributing to a strong balance sheet.
- For its MRT-8102 (NEK7 degrader) program, Monte Rosa announced an 85% drop in CRP levels and 94% normalization in obese individuals with elevated CRP, with Phase 2a data expected in the second half of the year.
- In oncology, the GSPT1 program showed a 100% response rate (5 out of 5 patients) in prostate cancer patients with androgen receptor mutations, with a confirmatory Phase 2 trial (MODIFIER-1) starting in Q3 this year.
- Novartis plans to initiate a Phase 2 program this year for the VAV1 program, which is partnered with Monte Rosa.
4 days ago
Monte Rosa Therapeutics Provides Update on Clinical Programs and Financial Position
GLUE
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Monte Rosa Therapeutics has three clinical programs (MRT-6160, MRT-8102, GSPT1) that have demonstrated positive clinical data, with plans to initiate multiple Phase II trials across these programs in 2026.
- The NEK7 degrader, MRT-8102, achieved an 85% reduction in CRP levels and 94% normalization in obese patients with elevated CRP, with data from the Phase IIa GFORCE-1 study expected in H2 2026 and a Phase IIb (GFORCE-2) initiation around the same time.
- In its GSPT1 oncology program, the company reported a 100% PSA response rate in five out of five metastatic castration-resistant prostate cancer patients with AR mutations, with a confirmatory Phase II trial (MODIFIER-1) set for Q3 2026 initiation.
- The company maintains a strong balance sheet, supported by over $300 million in collaboration revenue received in the last year and recent financing.
4 days ago
Monte Rosa Therapeutics Updates on Clinical Pipeline and Financial Position
GLUE
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Monte Rosa Therapeutics, a molecular glue degrader company, has 3 programs in the clinic, all of which have produced positive clinical data.
- The company plans to initiate Phase 2 trials for all 3 clinical programs this year.
- For its NEK7 degrader (MRT-8102), Monte Rosa reported an 85% drop in CRP levels and 94% normalization of CRP levels in a Phase 1 study, with no safety concerns. The Phase 1 trial has been expanded into a Phase 2a study (GFORCE-1), with data expected in the second half of the year, and a Phase 2b (GFORCE-2) study hoped to start around the same time.
- For its GSPT1 degrader (MRT-2359), 5 out of 5 patients with AR mutations showed a drop in PSA, with 2 achieving RECIST PRs. A confirmatory trial (MODIFIER-1) is scheduled for Phase 2 initiation in Q3.
- The company has a strong balance sheet, having generated over $300 million in collaboration revenue over the last year and completed a financing earlier this year. It also plans an IND submission for a second-generation NEK7 molecule and a cyclin E, CDK2 program by year-end.
4 days ago
Monte Rosa Therapeutics prices underwritten public offering
GLUE
- Monte Rosa Therapeutics priced an underwritten public offering of 11,125,000 shares of common stock at $24.00 per share and 1,375,000 pre-funded warrants at $23.9999 per pre-funded warrant.
- The offering is expected to generate approximately $300 million in gross proceeds for Monte Rosa, excluding any exercise of the underwriters' option to purchase additional shares.
- The offering is anticipated to close on or about January 12, 2026.
Jan 9, 2026, 3:49 AM
Monte Rosa Therapeutics Announces Proposed Public Offering
GLUE
- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) has commenced an underwritten public offering of $200.0 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.
- Monte Rosa also plans to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock.
- The offering is being managed by Jefferies, TD Cowen, and Piper Sandler as joint book-running managers.
- The proposed offering is subject to market and other conditions, and there is no assurance as to its completion, actual size, or terms.
Jan 7, 2026, 9:01 PM
Monte Rosa Therapeutics announces positive interim Phase I results for MRT-8102 in ASCVD
GLUE
New Projects/Investments
Guidance Update
- Monte Rosa Therapeutics reported positive interim results from its phase I study of MRT-8102, a NEK7-directed molecular glue degrader for atherosclerotic cardiovascular disease (ASCVD), showing no safety concerns in single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
- The study demonstrated a rapid and compelling reduction in high-sensitivity C-reactive protein (hsCRP), with an 85% sustained reduction observed in high CVD risk subjects after four weeks of dosing, and 94% of subjects achieving hsCRP levels below 2 mg/L. A 31% reduction in fibrinogen was also noted after four weeks of dosing.
- The company is expanding its phase I study, now named G-Force One, to explore additional dose levels and plans to initiate a phase II study (G-Force Two) for MRT-8102 in ASCVD in 2026.
- Data from the expanded G-Force One study are anticipated in the second half of 2026.
- Monte Rosa also highlighted progress in other pipeline programs, including MRT-6160 (licensed to Novartis) progressing to multiple phase II studies in immune-mediated diseases in 2026, and plans to initiate a phase II study for MRT-2359 in prostate cancer in 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Therapeutics Announces Positive Interim Phase I Results for MRT-8102 and Expansion of Clinical Program
GLUE
New Projects/Investments
- Monte Rosa Therapeutics announced that interim results from its phase I study of MRT-8102, a NEK7-directed molecular glue degrader, exceeded expectations, showing a rapid and compelling reduction in hsCRP and a 31% reduction in fibrinogen after four weeks of dosing in high CVD risk subjects.
- The study demonstrated a favorable safety profile for MRT-8102, with no serious adverse events and no evidence of increased infection risk across 112 subjects.
- The phase I study, now named GFORCE-1, will be expanded to explore additional dose levels, with data from this expanded study expected in the second half of 2026.
- Monte Rosa Therapeutics plans to initiate a phase II study, GFORCE-2, of MRT-8102 in ASCVD in 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Therapeutics Announces Positive Interim Phase I Results for MRT-8102
GLUE
New Projects/Investments
- Monte Rosa Therapeutics reported positive interim clinical results from its Phase I study of MRT-8102, a NEK7-directed molecular glue degrader, noting no safety concerns and a favorable safety profile across all cohorts as of the December 23, 2025 data cut-off.
- In subjects at high cardiovascular disease (CVD) risk, MRT-8102 demonstrated an 85% sustained reduction in high-sensitivity C-reactive protein (hsCRP) after four weeks of dosing, with 94% of subjects achieving hsCRP levels below 2 milligrams per liter. A 31% reduction in fibrinogen was also observed.
- The company is expanding the Phase I study, now named G-Force One, to include additional dose exploration of MRT-8102 in subjects with elevated CVD risk to accelerate development in atherosclerotic cardiovascular disease (ASCVD).
- Data from the expanded G-Force One study are expected in the second half of 2026, and a Phase II study (G-Force Two) of MRT-8102 in ASCVD is planned for 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Provides Update on MRT-8102 Phase 1 Study Results
GLUE
New Projects/Investments
- GLUE's MRT-8102, a NEK7-directed molecular glue degrader, demonstrated rapid and compelling reduction in hsCRP across all doses tested in healthy volunteers and high-CVD risk subjects, with no adverse safety signals observed as of December 23, 2025.
- Completed SAD and MAD cohorts showed ~80-90% NEK7 degradation in T cells at all dose levels and a 78% reduction in hsCRP in subjects with elevated baseline CRP levels.
- Preliminary data from the ongoing Part 3 (CRP PoC) of the Phase 1 study in high-risk CVD subjects indicated an 85% sustained reduction of hsCRP through week 4, with 94% of subjects achieving hsCRP levels below 2 mg/L and a 31% reduction of fibrinogen after 4 weeks of dosing.
- The study, now named GFORCE-1, will be expanded for accelerated development in ASCVD, with data expected in H2 2026, and plans to initiate the Phase 2 GFORCE-2 study in ASCVD in 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data for MRT-8102
GLUE
New Projects/Investments
- Monte Rosa Therapeutics, Inc. (GLUE) announced positive interim Phase 1 data for its NEK7-directed molecular glue degrader, MRT-8102, in subjects with elevated cardiovascular disease (CVD) risk.
- The data, with a cutoff of December 23, 2025, showed MRT-8102 reduced C-reactive protein (CRP) levels by 85% after four weeks of treatment, with 94% of participants achieving CRP values below 2 mg/L from a median baseline of 6.3 mg/L.
- A favorable safety profile was observed, characterized by mild to moderate adverse events and no evidence of increased infection risk.
- Monte Rosa plans to initiate a Phase 2 study for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) in 2026, with additional data from the GFORCE-1 study anticipated in H2 2026.
Jan 7, 2026, 12:06 PM
Quarterly earnings call transcripts for Monte Rosa Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more